16 September 2026 editorial review · Item
Autologous CD6-CAR regulatory T cells: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added distinct autologous engineered Treg programme. Read current registry intervention, sequential safety design, eligibility,15-year follow-up plan and status; City of Hope independently lists it under Coming Soon.
- Primary sources checked: NCT07395050 — study record (registry); City of Hope diabetes clinical trials — CD6-CAR Tregs coming soon (news).
- Limits: Estimated September dates passed; no start/completion inferred. No T1D outcomes. Results for allogeneic CD6-CAR Tregs in graft-versus-host disease do not establish this autologous T1D programme.